RT Journal Article
SR Electronic
T1 Asparagine metabolism in tumors is linked to poor survival in females with colorectal cancer: A cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.30.21265637
DO 10.1101/2021.10.30.21265637
A1 Shen, Xinyi
A1 Cai, Yuping
A1 Lu, Lingeng
A1 Huang, Huang
A1 Yan, Hong
A1 Paty, Philip B.
A1 Muca, Engjel
A1 Ahuja, Nita
A1 Zhang, Yawei
A1 Johnson, Caroline H.
A1 Khan, Sajid A.
YR 2021
UL http://medrxiv.org/content/early/2021/11/01/2021.10.30.21265637.abstract
AB Background or Purpose The interplay between the sex-specific differences in tumor metabolome and colorectal cancer (CRC) prognosis has never been studied and represents an opportunity to improve patient outcomes. This study aims to examine the link between tumor metabolome and prognosis by sex for CRC patients.Methods Using untargeted metabolomics analysis, abundances of 91 metabolites were obtained from primary tumor tissues from 197 patients (N=95 females, N=102 males) after surgical colectomy for stage I-III CRC. Cox Proportional Hazards (PH) regression models were applied to estimate the associations between tumor metabolome and 5-year overall survival (OS) and 5-year recurrence-free survival (RFS), and their interactions with sex.Results Eleven metabolites had significant sex differences in their associations with 5-year OS, and five metabolites for 5-year RFS (Pinteraction < .05). The metabolites asparagine and serine had sex interactions for both OS and RFS. Furthermore, sex-specific differences were found in the associations between prognosis and metabolic pathways. Notably, in the asparagine synthetase (ASNS)-catalyzed asparagine synthesis pathway, asparagine was associated with substantially poorer OS (hazard ratio [HR] = 6.39, 95% confidence interval [CI] = 1.78-22.91, P = .004) and RFS (HR = 4.36, 95% CI = 1.39-13.68, P = .01) for female patients only (Pinteraction, OS = .02, Pinteraction, RFS = .003). Similar prognostic disadvantages in females were seen in lysophospholipid and polyamine synthesis.Discussion or Conclusions Unique metabolite profiles indicated increased asparagine synthesis was associated with poorer prognosis for females only, providing insights into precision medicine for CRC treatment stratified by sex.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH 1R21CA223686-01 (CJ, SK) and American Cancer Society Research Scholar Grant 134273-RSG-20-065-01-TBE (CJ). This publication was also made possible by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. This work was also supported by the Lampman Research Fund in Yale Surgical Oncology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University IRB determined that this study was not considered Human Subjects Research and did not require IRB review (IRB/HSC# 1612018746).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe untargeted metabolomics data underlying this article is available at www.ebi.ac.uk/metabolights MTBLS1122, MTBLS1124, MTBLS1129, MTBLS1130. All other data and code will be shared on reasonable request to the corresponding author.